Clay Siegall, the president and CEO of a leading biotechnology company called Seattle Genetics, helped to found the company in 1998. He also serves as the chairman of the Board of Trustees and is responsible for leading the capital fundraising efforts to get the company off the ground at a rapid pace. Seattle Genetics had been a trailblazer in the field of antibody cancer therapies. In particular, Seattle Genetics recently secured accelerated approval from the U.S. Food and Drug Administration (FDA) in 2011 for ADCETRIS, which is a cutting edge cancer-fighting antibody.
Part of the reason that Dr. Siegall has been so effective at making Seattle Genetics one of the top names in biotechnology and cancer research and development is because he has such an impressive background. After receiving a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland, Dr. Siegall went on to work at the National Institute of Health and the Bristol-Myers Squibb Pharmaceutical Research Institute. He gained invaluable insight into the biotechnology industry along with unparalleled knowledge about viable antibody therapies. In recognition of his extensive experience and specialized knowledge, Dr. Siegall was specifically recruited for a position on the Board of Directors of Alder BioPharmaceuticals.
Seattle Genetics maintains it corporate headquarters in Bothell, Washington, but it has gained international recognition for its work to advance innovative cancer and other autoimmune disease therapies and treatments. When it comes to developing out of the box and effective treatments for autoimmune diseases, Seattle Genetics is one of the first companies that comes to mind in the industry. Under the vision and leadership of Dr. Siegall, this top notch company is poised to maintain and advance its position as one of the most respected leaders in the field of biotechnology and treatment of autoimmune diseases.
Learn More about Clay Siegall: